An interventional study of Virtual reality in Brain Injury, Virtual Reality and Behavior, sponsored by Hopital La Musse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Hopital La Musse · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Brain Injuries with a site in France — 18 open to participants now, 19 under way, none of them phase 3. Brain Injuries · France.
Among the 72 studies in Brain Injuries with a site in France, this one is the 35th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2026, is one of 26 with no phase, and was the 69th registered.
947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.
Browse Brain Injuries studies →18 of the 72 studies in Brain Injuries with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 17+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier St Anne · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 41 across 613 interventional studies indexed under Brain Injuries.
Median enrollment 46 across the 36 interventional studies, 124 across the 36 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 72 have an industry lead sponsor. The 10 most frequent:
Hopital La Musse is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Hopital La Musse has 1 study filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Brain Injuries with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07085403Hopitaux de Saint-MauriceLet's CO-OPerate! Together we Are Stronger | 2027-05-01 |
| NCT07127224Centre Hospitalier St AnneConsciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients) | 2027-05-05 |
| NCT07450404Central Hospital, Nancy, FrancePK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Brain Injuries with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acquired brain injuries (ABIs) frequently cause emotional and behavioral disorders that impair independence and quality of life, particularly in institutions. Virtual reality (VR), already used in various mental and neurological disorders, offers therapeutic potential that remains largely unexplored in this context.
Multisensory devices offer enhanced immersion that can potentially increase the relaxation and calming effect. Their use in specialized care home (SCH) could provide additional support for care.
The main objective of the study is to measure the effect of an 8-week multisensory VR relaxation program on the most significant emotional and behavioral disorders in adults with acquired brain injury living in SCH. The SCED method with multiple baselines across subjects (ABA) is used with three adult residents with ABCI and behavioral disorders living in SCH. The study consists of three phases (baseline, intervention, follow-up), during which the three main emotional and behavioral disorders of each resident are assessed weekly based on observations made throughout the week. Additional measures include the assessment of the socio-emotional profile by the care team (ECCSEG) and the emotional distress experienced by residents (QOLIBRI), collected twice per phase. The intervention consists of eight weeks of VR relaxation (VirtySens®), with two 15-minute sessions per week.
All measurements taken during the experiment will be anonymized and used only by the investigators, who are fully aware of the European GDPR (General Data Protection Regulation) concerning the protection of personal data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
VR
Other: Virtual reality
The intervention will consist of 8 weeks with two weekly virtual relaxation sessions using the VirtySens® multisensory device, lasting 15 to 20 minutes.
NPI-ES
The primary outcome measure is the weekly NPI-ES score, calculated for the three most prominent emotional and behavioral disturbances in each participant. This score is calculated from systematic observations made daily over five consecutive days, during two standardized periods of the day: (1) lunch and (2) a group activity in the afternoon.
Time frame: Twice a week, for 21 weeks
ECCSEG : The Geneva Scale of Socio-Emotional Behavior Changes
The Geneva Socio-Emotional Behavior Change Scale (ECCSEG) was developed by Beni et al. (2017) to assess socio-emotional disorders frequently encountered after a TBI, although it can also be used in other etiological contexts. The ECCSEG questionnaire is completed by the neuropsychologist together with the care team, which includes at least one registered nurse, one nursing assistant or medical-psychological assistant, one special education teacher, and one psychomotor therapist during weekly team meetings. The team agrees to evaluate the 22 items on each participant's questionnaire. A total score is then calculated by adding up all the scores per item. The ECCSEG questionnaire is completed twice per phase: midway through and at the end of the phase.
Time frame: in the middle and at the end of each phase of the SCED (baseline, intervention, follow-up). 6 evaluations
The QOLIBRI Emotion Questionnaire
The QOLIBRI Emotion Questionnaire is a tool specifically designed for people with brain injuries, which aims to gather subjective perceptions of patients' quality of life.
Time frame: Twice at baseline, twice during the intervention, and twice during follow-up (6 evaluations).
Sensory capsule satisfaction survey
Each resident is asked: "Are you satisfied with using the sensory capsule? On a scale of 1 to 5 (Likert). 1 = Not at all; 2 = A little; 3 = Moderately; 4 = Quite a lot; 5 = Very much." Why? Residents will answer this question twice during the intervention.
Time frame: Twice during the intervention
The Simulator Sickness Questionnaire (SSQ)
The Simulator Sickness Questionnaire (SSQ) is currently the gold standard test for objectively measuring cybersickness.
Time frame: Twice during the intervention
The RV Presence Questionnaire
The Presence Questionnaire (74): consisting of 19 items on a 7-point scale, it measures the feeling of presence.
Time frame: Twice during the intervention
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 0 months is below that.
Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Sep 2026, primary completion Dec 2026 → Sep 2026 and completion Feb 2027 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital La Musse